Naked-Eye Detection of Rare Point Mutations in DNA

Summary

This protocol permits the naked-eye identification of point mutated DNA in a 200-fold excess of wild type DNA molecules, by exploiting gold nanoparticles and paramagnetic microparticles.

Abstract

The protocol describes a naked-eye colorimetric test for the detection of somatic point mutations in an excess of wild type DNA. The future foreseen application of the method is the identification of rare mutations in circulating cell-free DNA from liquid biopsies, with a relevance in cancer diagnostics and stratification of oncological patients for personalized therapy. As a proof of concept, the test has been designed to detect the BRAF^V600E mutation in the BRAF gene, which is important to identify the sub-group of melanoma patients that can benefit from targeted therapies with BRAF inhibitors. However, this colorimetric test can be easily generalized to other somatic mutations of clinical relevance due to the use of universal detection probes, thus providing strong potential in oncological diagnostics.

The test detects 0.5% of BRAF^V600E in an excess of BRAF^WT DNA, which matches the sensitivity of some commercial instrumental assays. Such sensitivity is clinically relevant for diagnostic purposes, allowing the early identification of drug-sensitive patients. In contrast to commercial assays based on real-time PCR, this test requires minimal instrumentation and processing, as it can be performed on DNA amplified with a standard PCR (or isothermal techniques) and provides a naked-eye readout with a one-tube reaction of a few steps in only one hour. At present, the test has been used only on synthetic DNA samples. However, the latter have been designed to mimic a real sample amplified from circulating cell-free DNA, to favor the translation of the test to clinical diagnostics.

Introduction

The purpose of the method is to detect underrepresented point mutations in a DNA sample with a minimally instrumented methodology and a naked-eye readout. The final aim is to have a proof-of-principle assay, suitable for future applications in rapid tests for the detection of somatic mutations in circulating cell-free DNA (ccf-DNA) (e.g., from blood biopsy samples) for the early diagnostics and monitoring of cancer¹. Cancer-related somatic mutations represent an important cancer biomarker² and are present in a minor (yet very variable)³ fraction of ccf-DNA, making their identification challenging⁴. We chose, as a model target, the oncogenic mutation BRAF^V600E that causes the constitutive activation of BRAF kinase. This mutation is present in 80% of all BRAF mutated cancers⁵ and is generally represented in only <1% of circulating tumor DNA⁶. Identifying patients carrying this mutation is important as it is predictive of the therapeutic response to BRAF inhibitors. Therefore, several methods^7,8,9,10 to assess the BRAF mutation status have been developed, with sensitivities ranging from 0.01% to 2%.

The main advantage of this method over the state-of-the-art methods is that its detection is instrument-free (naked-eye), as opposed to instrumental detection of fluorescent molecules by real-time PCR. Another advantage is its efficiency in discriminating one single mutated DNA molecule in an excess of 200 wild type DNA molecules. This discrimination factor of 0.5% is superior¹¹ or matches¹² that of some laboratory-based or commercially available kits, based on an instrumental detection and it is, thus, relevant for clinical diagnostic applications. On the other hand, as a laboratory prototype test, the method relies on the manual control of temperature-sensitive steps. However, the number of steps and the total duration of the assay is limited, making its future implementation in automated microfluidic systems conceivable.

This proof-of-concept method has been developed using synthetic DNA molecules. For its efficient translation to the clinics, it should be validated by using real-world samples amplified from patients' blood biopsies. We note that the future application field of the method is not intended to be the direct analysis of unprocessed complex biological matrices, such as bodily fluids. From the latter, DNA needs to be extracted with standard methodologies, and then amplified and purified. Consequently, the starting material for the analysis will always be purified and amplified DNA, which is reasonably comparable, in terms of possible interfering substances, to a synthetic DNA sample, such as that used for the development of this method.

Protocol

1. Synthesis of gold nanoparticle probes

1. Synthesize 40 nm citrate capped gold nanoparticles, using two-steps standard seeding growth method as detailed below.
   1. Synthesize 15 nm citrate capped gold nanoparticles (AuNPs seeds) using the classical Turkevich–Frens method^13,14.
      1. Wash all glassware with aqua regia (HCl:HNO₃ in a 3:1 v/v ratio).
      2. Heat 250 mL of 0.25 mM HAuCl₄ to boil while uniformly stirring.
         CAUTION: HAuCl₄ is corrosive and toxic.
      3. Immediately add 25 mL of 38.8 mM Na₃∙citrate.
      4. Continue boiling and stirring for 30 min, while the solution turns to a red ruby color.
      5. Remove the solution from the heat and let cool to room temperature while stirring.
      6. Filter using 0.22 µm PTFE membrane syringe filters.
      7. Store at 4 °C in a glass bottle.
         NOTE: The experiment can be paused here.
   2. Synthesize 40 nm citrate capped gold nanoparticles (40 nm AuNPs) by seeding growth¹⁵.
      1. Prepare solution A: 390 µL of freshly prepared 0.1 M hydroxylamine sulfate with 13 mL of AuNP seeds in a total volume of 120 mL in H₂O.
         NOTE: The amount of AuNPs seeds needed to obtain the desired size can vary; it must be titrated for each new AuNPs seed stock.
         CAUTION: Hydroxylamine sulfate is corrosive, toxic, mutagenic, and hazardous to the environment. For handling: Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid breathing dust. Do not use with metal spatula or other metal items. For storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep away from metals.
      2. Prepare solution B: 12.25 mL of H₂O + 0.25 mL of 0.1 M HAuCl₄.
      3. Load solution B in a syringe and load the syringe in a syringe pump.
      4. Set the syringe pump parameters: diameter of the syringe in mm; flow rate: 90 mL/h; total volume: 10.80 mL (of which, 0.8 mL are the excess needed for system equilibration, i.e., tube filling).
      5. Start the syringe pump. After the initial 0.8 mL of solution B have filled the tubing and dropped out to a waste container, position the tube on top of the reaction flask containing solution A (kept under moderate and uniform stirring) and let solution B enter dropwise.
      6. Cap by adding 2.65 mL of freshly prepared 0.1 M Na₃∙citrate, and stir for 5 min.
      7. Concentrate the obtained 40 nm AuNPs by centrifuging at 2,460 x g for 18 min at 10 °C.
      8. Remove the supernatant by gently aspirating. Resuspend gently in the residual volume.
      9. Store at 4 °C.
         NOTE: The experiment can be paused here.
2. Functionalize 40 nm citrate capped gold nanoparticles by standard thiol chemistry¹⁶.
   1. Digest disulfide bond by incubating thiolated probe oligonucleotides (5′ T(30)–(O–CH₂–CH₂)₃–SH 3′) with 10 mM Tris(2-carboxyethil)phosphine (TCEP) at room temperature for 3 h under mild shaking (400 rpm).
   2. Incubate a large excess of the digested oligonucleotides overnight with 10 nM AuNPs, at room temperature under mild shaking (400 rpm).
   3. Bring the AuNPs-DNA mixture to 0.3 M NaCl in 10 mM phosphate buffer, pH 7.4, 0.01% SDS, by adding salt stepwise over a 10 h timespan, under mild shaking (400 rpm).
   4. Incubate overnight at room temperature under mild shaking (400 rpm).
   5. Wash the DNA-conjugated AuNPs 3 times with 0.25 M NaCl in 10 mM phosphate buffer plus 0.01% SDS, to remove the excess unbound oligonucleotides.
   6. Store the obtained universal probes-AuNPs at 4 °C until use.
      NOTE: The experiment can be paused here.
   7. Determine the density of DNA probes on the AuNPs using a commercial fluorescence-based assay
   8. Measure the concentration of AuNPs by UV-vis spectroscopy. In order to derive AuNPs concentration from the absorbance data, the Lambert & Beer’s Law (A=εbc) and published extinction coefficients for 40 nm AuNPs¹⁶ can be used.
   9. Characterize AuNPs probes by dynamic light scattering (DLS), and transmission electron microscopy (TEM).
      NOTE: The experiment can be paused here.

2. Colorimetric discrimination of BRAF^V600E rare mutation

1. Prepare target samples for analysis: mixtures of synthetic BRAF^V600E DNA and BRAF^WT DNA at different ratios (BRAF^V600E:BRAF^WT 1:10, 1:100, 1:200, BRAF^V600E 100%, BRAF^wt 100%).
2. Equilibrate paramagnetic microparticles by washing them twice with hybridization buffer (HB) (1x PBS pH 7.4, 5% w/v PEG 600) and resuspend them in a volume of HB equal to the starting volume. For washing, put an aliquot of paramagnetic microparticles in a 1.5 mL tube (maximum 50 µL/tube), add 500 µL of HB and mix three times by gently pipetting, apply the magnet, separate the clear supernatant, immediately add 500 µL of HB and repeat the procedure for a second washing step. After removing the supernatant, immediately add the HB to avoid bead drying, as advised by the manufacturer.
3. For each sample to be tested, prepare a tube containing 2.5 µL of washed paramagnetic microparticles in HB.
4. Functionalize paramagnetic microparticles by incubating 2.5 µL of paramagnetic microparticles with 10 µL of a 10 µM solution of a biotinylated first discriminating probe (DP1), harboring BRAF^V600E mutation, for 5 min at room temperature.
5. Magnetically separate the microparticles from interfering unbound probes and resuspend them in 12.5 µL of HB. To this aim, apply the magnet to the side of the tube, and wait until the solution is transparent. Remove the solution by carefully pipetting, immediately add HB and gently pipette until the beads are homogeneously resuspended.
6. Add to the suspension 10 µL of a 10 µM mixture of the DNA target samples described in step 2.1.
7. Incubate for 30 min at room temperature.
8. During the incubation, shake samples every 3 min to avoid sedimentation of the paramagnetic microparticles.
9. Add to the suspension 10 µL of a 2 µM solution of a second discriminating probe (DP2), designed to have a portion complementary to the target and a poly-A tail.
10. Incubate for 15 min at room temperature.
11. During the incubation, shake samples every 3 minutes to avoid sedimentation of the paramagnetic microparticles.
12. Magnetically separate excess DP2 after incubation.
13. Add immediately 300 fmol of AuNPs conjugated with detection probes and incubate at room temperature for 5 min.
14. Magnetically separate supernatant containing excess AuNPs and perform the 1^st washing step by adding 100 µL of HB at room temperature.
15. Magnetically separate the supernatant and perform a 2^nd washing step by adding 100 µL of HB.
16. Incubate at 52 °C for 5 min.
17. Magnetically separate supernatant at 52 °C.
18. Resuspend immediately in 12.5 µL of HB for the readout of the colorimetric result.
19. Photograph results and store the samples at 4 °C.

Results

This method was used for the detection of BRAF^V600E mutation in an excess of BRAF^wt synthetic DNA. Figure 1 shows the details of the detection strategy. The assay gives a colorimetric YES/NO result^17,18 where red corresponds to a positive result (YES) and yellow to a negative one (NO).

Briefly, streptavidinated paramagnetic microparticles were coated with biotinylated discriminating p...

Discussion

The core aspect of the method is the ability to discriminate a target DNA in the context of an excess of interfering non-target DNA, where target and non-target DNA only differ for one single nucleotide. Thus, the design of the probes and the hybridization conditions are critical to achieve a sensitive discrimination. The assay is designed to use universal colorimetric probes to be adapted to the detection of any point mutations of interest. However, it is possible that some minor optimization of the reaction conditions ...

Materials

Name	Company	Catalog Number	Comments
Bench Top Centrifuge- Allegra X 30	Beckman Coulter	A99473
DL-Dithiothreitol	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	D0632-25G
Dynabeads M-280 streptavidin paramagnetic microparticles	Invitrogen	11205D
Hydroxylamine sulfate	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	379913-25G
KDS 100 Legacy Syringe Pump	kdScientific	789100
NanoDrop OneC spectrophotometer	Thermo Fisher Scientific Inc.,Waltham, MA, USA)
Phosphate Buffered Saline	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	806552-500ML
Pierce™ TCEP-HCl, No-Weigh™ Format	Thermo Fisher Scientific Inc.,Waltham, MA, USA)	A35349
Polyethylene glycol 600	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	202401
PTFE 0,22 µm filters, Fluoropore	Millipore	FGLP04700
Quant-iT™ OliGreen™ ssDNA Assay Kit	Thermo Fisher Scientific Inc.,Waltham, MA, USA)	O11492
Sodium citrate dihydrate	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	W302600
Synthetic oligonucleotides	Integrated DNA Technologies, Inc. (IDT DNA)
Tetrachloroauric(III) acid	Sigma-Aldrich/ Merck KGaA, Darmstadt, Germany	520918
Thiolated polyT DNA probes	Integrated DNA Technologies, Inc. (IDT DNA)
Transmission electron microscopy (TEM)	JEOL JEM 1011 microscope
Zetasizer Nano S - Dynamic Light Scattering System	Malvern Panalytical